Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1331
Article Code: 1331c
Date: February 8, 2010
Volume: 52
Pages: 11-12
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1331
Article Code: 1331c
Date: February 8, 2010
Volume: 52
Pages: 11-12
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)